Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 2/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 2/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23422044 | 0.86 | FFAR2 (0.38) | CSNK2A2KDRCSNK2BCSNK2A1HCAR2 | |
| SCHEMBL21836283 | 0.82 | ALDH1A1 (0.42) | CSNK2A2KDRCSNK2BCSNK2A1HCAR2 | |
| SCHEMBL4292895 | 0.80 | HCAR2 (0.42) | CSNK2A2KDRCSNK2BCSNK2A1HCAR2 | |
| SCHEMBL1107386 | 0.80 | HCAR2 (0.68) | CSNK2A2KDRCSNK2BCSNK2A1HCAR2 | |
| SCHEMBL274346 | 0.79 | CDC7 (0.59) | LMNAMAPK1ALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL21912862 | 0.79 | ALDH1A1 (0.55) | HCAR2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL324369 | 0.79 | — | — | |
| SCHEMBL2583653 | 0.78 | ALDH1A1 (0.49) | CSNK2A2KDRCSNK2BCSNK2A1HCAR2 | |
| SCHEMBL23146191 | 0.78 | HCAR2 (0.41) | CSNK2A2KDRCSNK2BCSNK2A1HCAR2 | |
| SCHEMBL33099 | 0.78 | KDM4E (0.43) | CSNK2A2KDRCSNK2BCSNK2A1HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 540 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041730-B1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4727546-A2 | PROTEOSOME COMPLEX INHIBITORS TARGETING CLPP1P2 PROTEASE | The Global Alliance for TB Drug Development, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12600716-B2 | Compounds for modulating activity of FXR and uses thereof | GANNEX PHARMA CO. LTD. (CN) | 2026-04-14 | — | — | US | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12583851-B2 | Heteroaryl-substituted pyrazine derivatives as pesticides | ELANCO ANIMAL HEALTH GMBH (DE) | 2026-03-24 | — | — | US | disclosed |
| EP-4073070-B1 | COMPOUNDS FOR MODULATING ACTIVITY OF FXR AND USES THEREOF | GANNEX PHARMA CO LTD (CN) | 2026-02-18 | — | — | EP | disclosed |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | SHANGHAI DEGRON BIOMEDICAL TECH CO LTD (CN) | 2026-02-05 | — | — | US | disclosed |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | BAYER AKTIENGESELLSCHAFT (DE) | 2026-02-03 | — | — | US | disclosed |
| EP-4676923-A1 | BIARYLAMIDE DERIVATIVES AND THEIR USE AS PKMYT1 INHIBITORS | Cancer Research Technology Limited (GB) | 2026-01-14 | — | — | EP | disclosed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| WO-2006015124-A2 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050250784-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-11-10 | — | — | US | disclosed |
| US-20050234033-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS | 2005-10-20 | — | — | US | disclosed |
| WO-2005086898-A2 | INHIBITORS OF HISTONE DEACETYLASE | MIIKANA THERAPEUTICS, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| US-20050197336-A1 | Inhibitors of histone deacetylase | MIIKANA THERAPEUTICS CORPORATION | 2005-09-08 | — | — | US | disclosed |
| WO-2005075469-A1 | THIAZOLYL-HYDROXAMIC ACIDS AND THIADIAZOLYL-HYDROXAMIC ACIDS, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY | ARGENTA DISCOVERY LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005075469-A1 | THIAZOLYL-HYDROXAMIC ACIDS AND THIADIAZOLYL-HYDROXAMIC ACIDS, AND USE THEREOF FOR TREATING DISEASES ASSOCIATED WITH HISTONE DEACETYLASE ENZYMATIC ACTIVITY | ARGENTA DISCOVERY LIMITED (GB) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005026149-A1 | PYRROL DERIVATIVES WITH ANTIBACTERIAL ACTIVITY | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| US-4089865-A | Certain thiazole compounds | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
| US-4001421-A | THIAZOLE CARDIOVASCULAR AGENTS | SYNTEX (U.S.A.) INC. (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583851-B2 | Heteroaryl-substituted pyrazine derivatives as pesticides | CBR3, CYCS, CWC15 | CSNK2A2 751/4885KDR 4066/4885CSNK2B 739/4885 |
| US-12600716-B2 | Compounds for modulating activity of FXR and uses thereof | FXR1, NR1H4, FXR2 | CSNK2A2 1687/4885KDR 2866/4885CSNK2B 1598/4885 |
| US-20050197336-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | CSNK2A2 193/4885KDR 4733/4885CSNK2B 167/4885 |
| US-12540134-B2 | Inhibitors of adrenoreceptor ADRAC2 | ADRA2C, ADRB3, ADRB2 | CSNK2A2 715/4885KDR 1193/4885CSNK2B 735/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | CSNK2A2 2186/4885KDR 819/4885CSNK2B 1827/4885 |
| US-20260035361-A1 | COMPOUNDS FOR MODULATING HUR (ELAVL1) | ELAVL1, ELAVL3, HNRNPL | CSNK2A2 1728/4885KDR 2640/4885CSNK2B 1774/4885 |
| US-20050250784-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | CSNK2A2 193/4885KDR 4733/4885CSNK2B 167/4885 |
| US-20050234033-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC11, HDAC10 | CSNK2A2 193/4885KDR 4733/4885CSNK2B 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.